Emcure Pharmaceuticals growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr
Revenue+16.6%
EBITDA+26.5%
Net Income+33.1%
EPS (adj.)+35.7%
Total Assets+16.8%
Total Equity+7.2%
Free Cash Flow−11.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

EMCURE₹1,865.00

Emcure Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersMANKINDALKEMTORNTPHARMERISGRANULESCONCORDBIOINDGNCAPLIPOINTMcap ₹35,359 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
Revenue+16.6
EBITDA+26.5
Net Income+33.1
EPS (adj.)+35.7
Total Assets+16.8
Total Equity+7.2
Free Cash Flow-11.0
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.